BIIB Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of 20.1%. Biogen, Inc.'s return on equity of 9.36% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Biogen, Inc. has a consensus price target of $182.83, signalling upside risk potential of 0.12%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $490.50 which suggests that it could grow by 20.69%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.539%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are larger than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Biogen, Inc.'s net income of $466.5M is higher than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.65x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,689.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.76x versus 16.67x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 19% compared to Biogen, Inc.'s net margin of 31.72%. Biogen, Inc.'s return on equity of 9.36% beat Eli Lilly & Co.'s return on equity of 106.26%.

Biogen, Inc. has a consensus price target of $182.83, signalling upside risk potential of 0.12%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,098.04 which suggests that it could grow by 3.2%. Given that Eli Lilly & Co. has higher upside potential than Biogen, Inc., analysts believe Eli Lilly & Co. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Biogen, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.5B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Biogen, Inc.'s net income of $466.5M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.65x while Eli Lilly & Co.'s PE ratio is 52.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.76x versus 16.33x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of 21.32%. Biogen, Inc.'s return on equity of 9.36% beat Pfizer Inc.'s return on equity of 10.84%.

Biogen, Inc. has a consensus price target of $182.83, signalling upside risk potential of 0.12%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 12.56%. Given that Pfizer Inc. has higher upside potential than Biogen, Inc., analysts believe Pfizer Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.76% to investors and pays a quarterly dividend of $0.43 per share. Biogen, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Biogen, Inc.'s net income of $466.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.65x while Pfizer Inc.'s PE ratio is 14.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.76x versus 2.31x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of 19% compared to Biogen, Inc.'s net margin of -360.68%. Biogen, Inc.'s return on equity of 9.36% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Biogen, Inc. has a consensus price target of $182.83, signalling upside risk potential of 0.12%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $34.25 which suggests that it could fall by -2.75%. Given that Biogen, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Biogen, Inc. is more attractive than Stoke Therapeutics, Inc..

Biogen, Inc. has a beta of 0.127, which suggesting that the stock is 87.301% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.227%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.5B, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Biogen, Inc.'s net income of $466.5M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Biogen, Inc.'s price-to-earnings ratio is 16.65x while Stoke Therapeutics, Inc.'s PE ratio is 53.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 2.76x versus 9.99x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.